@conference{
author = "Drndarević, Aneta and Draganov, Ivana and Miljković, Branislava and Davidović, Aleksandar and Cvijanović, Dane and Savković, Tatjana and Vezmar-Kovačević, Sandra",
year = "2022",
abstract = "Clinically significant drug-drug interactions (DDIs) are expected in patients with
cardiovascular diseases due to the number of drugs in therapy. The aim of the research was
to analyze DDIs during treatment which preceeded the admission to the cardiology
department. In the cardiology department of the Clinical Hospital Center Zvezdara, the
treatment of patients with ≥2 drugs before admission was analyzed. DDIs were identified
using the Lexicomp database (Lexi-Interact). Data were analyzed descriptively and with
linear regression analysis. During research, out of 132 participants 88.6% had ≥1, while
41.7% had ≥5 DDIs. The total number of DDIs was 648 (median 3, range 0-19). Men
constituted 64.4% of the population, with a median age of 70 years (32-90). Patients had 4
diagnoses (1-13) and 6 medications on admission (2-15). In 3.8% of patients,
contraindicated DDIs of anticholinergics were observed, 23.5% had DDIs that required
caution or a change in therapy, while interactions requiring follow-up were observed in
86.4% of patients. Angiotensin-converting enzyme inhibitors (30.4%), acetylsalicylic acid
(26.6%) and loop diuretics (16.5%) were most frequently involved in DDIs, while the most
common adverse events could be renal failure (21.5%), hypotension 19.7%) and bleeding
(13.7%). The number of drugs in therapy was a predictor of DDIs (p <0.001). Patients with
cardiovascular disease are often exposed to polypharmacy and consequently DDIs.
Cardiovascular drugs were most frequently involved in DDIs, but contraindicated DDIs were
present in anticholinergic drugs. In patients with cardiovascular diseases, monitoring of
renal function, hypotension and bleeding is required., Klinički značajne interakcije (KZI) očekuju se kod pacijenata sa kardiovaskularnim
bolestima usled većeg broja lekova u terapiji. Cilj istraživanja je bio da se identifikuju i
analiziraju KZI pacijenata koje su prethodile prijemu na odeljenje kardiologije. U Kliničko-
bolničkom centru Zvezdara, na odeljenju kardiologije, analizirana je terapija pacijenata sa ≥2
leka pre prijema. KZI su identifikovane upotrebom baze Lexicomp (Lexi-Interact). Podaci su
analizirani deskriptivno i primenom linearne regresione analize. Od 132 učesnika u
istraživanju 88,6% je imalo ≥1, dok je 41,7% imalo ≥5 KZI. Ukupan broj KZI bio je 648
(medijana 3, opseg 0-19). U populaciji je bilo 64,4% muškaraca medijane starosti 70 godina
(32-90). Pacijenti su imali 4 dijagnoze (1-13) i 6 lekova na prijemu (2-15). Kod 3,8%
pacijenata utvrđene su KZI antiholinergika koje se smatraju kontraindikovanim. Približno
jedna četvrtina pacijenata (23,5%) je imala KZI koja zahteva oprez ili izmenu u terapiji dok
su kod 86,4% pacijenata uočene interakcije koje zahtevaju praćenje ishoda. Najčešće su u KZI
stupali inhibitori angiotenzin-konvertujućeg enzima (30,4%), acetilsalicilna kiselina (26,6%)
i diuretici petlje (16,5%) dok su najčešći neželjeni ishodi mogli biti bubrežna insuficijencija
(21,5%), hipotenzija (19,7%) i krvarenje (13,7%). Broj lekova u terapiji bio je prediktor za
KZI (p<0,001). Pacijenti sa kardiovaskularnim bolestima su često izloženi polifarmaciji i
posledično većem broju KZI. U KZI su najčešće stupali lekovi u terapiji kardiovaskularnih
bolesti ali su kontraindikovane KZI bile zastupljene kod antiholinergičkih lekova. Kod
pacijenata sa kardiovaskularnim bolestima potrebno je praćenje renalne funkcije,
hipotenzije i krvarenja.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Clinically significant drug-drug interactions in the treatment of cardiovascular diseases on hospital admission, Pregled klinički značajnih interakcija u terapiji kardiovaskularnih bolesti kod pacijenata na prijemu u bolnicu",
volume = "72",
number = "4 suplement",
pages = "S223-S224",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4506"
}
